A Phase 1b, Open-Label, Dose Escalation Study of ADG116 in Combination With Pembrolizumab (Anti-PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors
Latest Information Update: 29 Feb 2024
At a glance
- Drugs ADG 116 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Proof of concept
- Acronyms KEYNOTE C97
- Sponsors Adagene
- 20 Apr 2023 Status changed from recruiting to completed.
- 10 Nov 2022 According to an Adagene media release, data from the trial were presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022).
- 10 Nov 2022 Results presented in an Adagene media release.